CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CENTRESTAGE 10th anniversary set to dazzle in September
CENTRESTAGE 10th anniversary set to dazzle in September

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), the four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The  Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康哲药业（867.HK，8A8.SG）上半年营收净利双升 战略转型跑出增长新动能
康哲药业（867.HK，8A8.SG）上半年营收净利双升 战略转型跑出增长新动能

深圳，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 8月18日，康哲药业发布2025年中期业绩，公司营收和利润同比均实现增长，战略转型成效初显。报告期内，公司实现营业收入约40.0亿元（人民币，下同），同比增长10.8%。若全按药品销售收入计算则营收约46.7亿元，同比增长8.9%。实现净利润约9.3亿元，同比增长3.1%。具体来看，康哲药业已走出国采阴霾，业绩将回归持续上升轨道。公司主要非国采独家/品牌产品及创新产品全按药品销售收入合计约29.0亿元，同比增长20.6%，占总收入比重升至62.1%。公司独家/品牌产品、创新产品竞争格局良好、增长可预期性强，目前已成为拉动业绩向上的主力军。根据业绩公告，公司自2018年起擘画"新康哲"转型蓝图，以"产品创新、商业革新、国际拓展"三大战略为支柱，构建可持续的第二增长曲线。行至2025年上半年，良好的经营业绩及创新成果持续落地，证实战略升级已逐步兑现为硬核战果。"新产品"战略推动创新价值兑现 夯实增长后劲立于公司三大战略之首的"产品创新"战略，依托"海外授权+国内合作+自主研发"三维创新机制，持续注入高价值短、中、长期管线，成为驱动增长的重要引擎。目前，创新战略已进入持续收获期，新产品正不断释放商业与临床价值。截至目前，公司已有5款创新药成功于中国实现商业化；2025年内，芦可替尼乳膏和德昔度司他片两款创新产品亦有望获批上市。芦可替尼乳膏是美国FDA以及欧洲EMA批准的首个、也是唯一一个局部JAK抑制剂非节段型白癜风复色产品，有望成为中国获批上市的首款白癜风治疗药物，将填补市场空白，为中国白癜风患者带来新希望。此外，阿尔茨海默病新药ZUNVEYL的中国上市申请(NDA)亦已于今年7月获受理；消费医疗产品注射用聚左旋乳酸微球填充剂已获得上市批准，进一步丰富公司多元化产品矩阵。在研创新管线中，已有多款重磅候选药物进入中国后期临床开发阶段，预计将在未来1-3年内陆续进入商业化，形成持续放量的新动力。其中，合作产品注射用Y-3已完成中国III期临床，该产品为原创单分子1类新药，亦为全球唯一进入临床研究的非肽类PSD95/nNOS解偶联剂，并有望成为首个治疗缺血性卒中并预防卒中后抑郁焦虑的双功能脑细胞保护药物。另一个口服小分子1类新药ABP-671（URAT1抑制剂）用于治疗痛风及高尿酸血症，目前其中国IIb/III期临床正有序推进中。相较现有主流药物，该产品有潜力以更低剂量将尿酸降低至更低水平，并具有溶解痛风石的能力，有望为患者提供疗效更优、安全性更高的治疗选择。康哲药业亦持续增厚创新储备，不断夯实全链条创新实力，以实现创新产品分阶段、源源不断获批上市。2025上半年，公司新增ZUNVEYL、MG-K10（长效抗IL-4Rα人源化单抗注射液）两款合作开发创新产品。截至目前，公司累计布局约40款差异化创新管线，其中约20项为自主研发项目。同步推进"新模式"、"新地域"战略 拓展多维增量空间根据业绩公告，康哲药业持续推进"新模式-商业革新"战略，以多元生态锻造抗周期韧性；并坚定执行"新地域-国际拓展"战略，以产业国际化出海模式构建多维增长格局。在商业革新战略下，公司持续聚焦专科领域，同时拓展新零售、新媒体渠道，构建"院内+院外"、"线上+线下"全覆盖的营销推广体系，并持续强化消费医疗产品布局。公司皮肤健康业务"德镁医药"已在这一具消费属性的赛道崭露头角，自2021年独立运营以来，已实现皮肤疾病领域适应症覆盖广度、皮肤处方药收入规模的双重领先，将通过介绍上市、实物分派方式，拟分拆于香港联交所主板独立上市，进一步释放其独立价值与高成长潜力。国际化方面，2025年7月15日，公司以介绍方式成功于新加坡交易所完成第二上市，"产业国际化"战略迈入新里程。以新加坡为枢纽，公司构建起覆盖"研-产-销"的新兴市场全链条业务体系。截至目前，商业化平台公司Rxilient已在东南亚、中东、港澳台等地区累计提交近20款药品和器械注册申请，涵盖皮肤科、眼科、肿瘤、自免、中枢神经等领域。芦可替尼乳膏（白癜风适应症）已在澳门、香港获批，并已递交新加坡、台湾注册申请；静脉注射用特瑞普利单抗（首个被中国NMPA及美国FDA批准上市的国产抗PD-1单抗药物）已提交马来西亚等五国注册申请；替瑞奇珠单抗注射液、蔗糖羟基氧化铁咀嚼片亦在香港获批。同时，公司持股45.0%的联营CDMO生产工厂PharmaGend，目前已具备片剂、胶囊等口服固体制剂年产10亿片的能力，并获得新加坡HSA颁发的生产许可证、美国FDA cGMP认证及瑞士QP审计通过。PharmaGend鼻喷剂、乳膏、注射剂等新产线的建设正稳步推进中，为国际市场提供高标准生产交付能力。展望未来，"新康哲"增长逻辑有望加速兑现，盈利能力与业绩韧性将同步提升。公司正构建以差异化创新为核心、多元生态协同驱动、国际化布局支撑的增长体系，为高质量发展打开长期空间，为全球患者提供高品质医药产品和服务，为股东带来可持续回报。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，其中皮肤健康业务已成为该细分领域的龙头企业，带来专科规模效率。同时，康哲药业持续深化东南亚及中东区域业务发展，助力高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.

The 35th Food Expo and concurrent fairs attract over 500,000 visits
The 35th Food Expo and concurrent fairs attract over 500,000 visits

- The Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today, bringing together approximately 1,890 exhibitors and welcoming over 500,000 visits.- The per capital spending across the five fairs reached HK$1,630.- 48% of respondents believe that health, green and organic food trends are worth paying attention to. Halal food and beverage label at the expo helps promote the development of halal foods.- The five theme days, along with a series of exciting activities effectively boosted local consumption and created a bustling atmosphere.- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) featured 21 prominent speakers who shared innovative achievements and development trends in the globalisation of Chinese medicine.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today. Food Expo PRO and the Hong Kong International Tea Fair, which opened to both industry professionals and the public for the first time, wrapped up successfully on 16 August. The five exhibitions featured some 1,890 exhibitors and attracted over 500,000 visits. The bustling atmosphere resulted in a per capita spending of HK$1,630, once again demonstrating the appeal of this annual event and the public’s purchasing power. Over at Food Expo PRO and the Hong Kong International Tea Fair, there were some 18,500 buyers from 64 countries and regions. Apart from Hong Kong, buyers came from Mainland China, Japan, Korea, Taiwan, as well as ASEAN countries, including Cambodia, Malaysia, the Philippines, Thailand, and Vietnam, among others, highlighting Hong Kong's significant role as a key food trade hub globally. Additionally, the International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also concluded successfully on 15 August.Sophia Chong, HKTDC Deputy Executive Director, stated: "This year, the event featured five major themes across several exhibitions, complemented by a variety of exciting activities that encouraged people to spend locally. The atmosphere was vibrant, fully reflecting the public's enthusiasm for gourmet food and trendy products. Due to weather conditions on the first day, the opening hours of the public fairs from Friday to Sunday were extended to provide exhibitors with greater opportunities to maximise sales and enhance visitor experiences. The Hong Kong International Tea Fair, which opened to the public over all three days for the first time, attracted significant attention and praise.”Despite challenges from sluggish trade in traditional markets and geopolitical challenges, the HKTDC has consistently focused on driving innovation, helping small and medium-sized enterprises seize global development trends, and creating opportunities through innovative and flexible thinking.Ms Chong added: “At this year's Food Expo and Food Expo PRO, we specifically curated products and services related to halal food, the silver economy, and food technology to meet emerging market demands and capture more business opportunities for exhibitors. We are pleased to see that the five exhibitions successfully generated more business for exhibitors, and the public enjoyed the culinary and shopping experience fully."Per capita spending reached HK$1,630; increased interest in halal foodsDuring the exhibition, the organisers conducted a random sampling survey, interviewing some 1,440 visitors. The per capita spending reached HK$1,630. Over 58% of respondents reported spending HK$1,000 or more at the exhibition, and over 30% indicated that their actual spending exceeded their original budget, demonstrating a strong and thriving consumption atmosphere during the event. The survey results also showed respondents believe that health, green and organic food (48%), and nutritional supplements (36%) trends are worth paying attention to. Among the respondents who are aware that the exhibition has a halal food and beverage label, more than half of the respondents (52%) believe it helps promote the development of halal foods.Vibrant consumption at the exhibition: encouraging sales performanceAs a highly anticipated annual event in the city, the Food Expo is dedicated to highlighting exquisite delicacies and fine wines from around the world. Director of exhibitor Yick Cheong Ho (HK) Limited, Joan Chui, stated that the Flavours of Intangible Cultural Heritage theme day has drawn extra interest and expected revenue of approximately HK$900,000. Some exhibitors are further expanding their business through the Food Expo. Huaying Lei, the chairman of Mayang Blue Phoenix Agricultural Development Co., Ltd from Mainland China stated that the company had signed a RMB60 million contract with a Hong Kong client for agri-products including high-quality edible eggs. Lei believed the Food Expo offers a perfect platform to showcase their wide-ranging products from Hunan Province.The concurrently held Beauty & Wellness Expo offered visitors a diverse range of premium products, with brand Mars, a Taiwan whey protein brand, the brand marketing manager Roy Wong said, “This year, the visitor traffic exceeded our expectations and we expect our on-site sales will increase by 30% to HK$200,000.”The Home Delights Expo showcased a variety of trendy household items and furniture. Andy Tsang, the design director of Renovation Guide Consultant Limited - specialising in interior design and decoration and participating in the expo for the first time - said, “Such a large number of new customers visiting our booth went above and beyond our expectations. We provided quotations to over 20 new clients, and we estimate that sales turnover will be around HK$2-3 million."Trade exhibitions expand business networks; thriving opportunities in halal foodThe 3rd Food Expo PRO and the 35th Food Expo introduced halal food and beverage label last year to help exhibitors expand their market for halal products. This year, more than 120 food suppliers showcased halal products from around the world, a 20% increase compared to last year. Daniel Chan, Director of Hong Kong exhibitor, Koon Chun Hing Kee Soy & Sauce Factory Ltd., said the company had seen many buyers from different countries and regions and discussed cooperations with five Mainland China and local distributors and restaurants and also met a buyer from Indonesia through the Click2Match platform.The new "Coffee" zone also debuted this year, showcasing coffee products, accessories, and machines from various origins. Jin Lu, Operations Director of CSFA Holdings Shanghai Co. Ltd., stated that the company has engaged with nine exhibitors from Mainland China, the U.S., South Korea, and other regions. The company is interested in placing a coffee beans order of approximately 50 metric tons (worth around RMB3 million) from a Yunnan-based supplier, as well as a RMB700,000 order for premium hairtail fish from a Korea exhibitor.The highlight zone, "Food Science and Technology," brought alternative and future food to the attention of professional buyers. My Care Healthcare Limited, a manufacturer of modified soft diet products for the elderly. Founder Francis Ho said they had discussions with nearly 120 buyers on the first day. On the last day of the fair, HKTDC arranged specialised medical industry buyer tours of which there were two potential buyers and the company is in talks with two hospitals to discuss the potential of supplying soft meals to them.The Okinawa Prefectural Government Hong Kong Representative Office organised four Okinawan companies to participate in the Food Expo PRO and successfully connected with buyers from Hong Kong, Mainland China, and international markets. Director Yasutoshi Nohara stated the fair helps them generate around HK$4 million in orders every year. Mr Nohara said the expo has been instrumental in providing them with a great opportunity, particularly to introduce Okinawan products in the Greater Bay Area and expand beyond Hong Kong with items that have not been shown in other markets before, such as soft shell turtle and Motobu beef.Sichuan Sentaiyuan Biotechnology Co., Ltd. has participated in the Food Expo PRO for four consecutive years, promoting healthy products. The company’s CEO, Liu Lei shared, “On the first day of the Expo, we met a long-time Hong Kong client in person for the first time, leading to a successful deal worth over US$5 million. The HKTDC also introduced several potential buyers from Japan, Singapore, and other regions and we expect deals to be finalised soon.” Mr Lei also mentioned that through the hktdc.com Sourcing platform, the company received around 30 inquiries before the expo and arranged on-site meetings with several clients. The “EXHIBITION+” hybrid model has significantly boosted the company’s visibility and secure more business opportunities.The Hong Kong International Tea Fair opened to trade and public visitors on all three days for the first time. Yip Wing-chi, Founder of exhibitor, Lock Cha Tea House, welcomed this arrangement and noted that there was a significant increase in traffic, creating a lively atmosphere. The public participation has effectively boosted business. Mr Yip said this year's sales were three times higher than last year.Hybrid model connecting local and overseas opportunitiesThis year, both Food Expo PRO and the Hong Kong International Tea Fair continued to adopt the EXHIBITION+ hybrid model, enabling global food and tea buyers to engage in business discussions through both physical exhibitions and online platforms. Until 23 August, exhibitors and buyers can still utilise the "Click2Match" smart matching platform for online discussion and to explore business opportunities.Chinese Medicine Conference Gathers Experts and Scholars to Promote Industry ExchangeThe International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association in partnership with the HKTDC and ten scientific research institutions, has successfully concluded. The conference unveiled the latest professional information on traditional Chinese medicine and shared innovative achievements and development trends in the globalisation of Chinese medicine. Held concurrently with the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO, and the Hong Kong International Tea Fair, the event covered diverse fields such as food, beauty, health, home products, and Chinese medicine, successfully creating a synergistic effect, providing a broad platform for industry exchange.Photo download: http://bit.ly/4mrgT4SThe Food Expo, Home Delights Expo, and Beauty & Wellness Expo, three public exhibitions organised by the Hong Kong Trade Development Council, along with the Food Expo PRO and the Hong Kong International Tea Fair, have successfully concluded, attracting over 500,000 visits to attend and shopThe Food Expo PRO featured multiple pavilions showcasing unique culinary delights from different countries and regions, with exhibitors displaying halal food and beverage label gaining increasing attentionThe Federation of Hong Kong Industries and the Incorporated Trustees of the Islamic Community Fund of Hong Kong launched the “Hong Kong Q-Mark Halal Scheme” at the Food Expo PRO, announcing their joint efforts to promote halal certification and its development, fostering the sustainable development of halal products and culture in Hong KongAt the Food Expo PRO, the HKTDC signed a Memorandum of Understanding with The Bank of Saga Ltd., to promote businesses in Saga, Fukuoka, and Nagasaki to further their development in Hong Kong and beyond, revitalising both the local economy and prosperity of the regionThe Hong Kong International Tea Fair opened to the public for the first time over its three-day exhibition period, drawing many visitors to explore a variety of tea beveragesThe five major theme days ran throughout the exhibition period, with the opening day (14 August) featuring "Shall We Tea'”, focusing on demonstrations of Northern and Southern dim sum and creative dim sum making, tea therapy workshops and other exciting activitiesOn 15 August, “Flavours of Intangible Cultural Heritage” featured hands-on experiences in making traditional Hakka “hand-pulled” noodles, as well as introductions to intangible cultural heritage steamer and bamboo craftmanship culture, along with steamer craft demonstrationsOn 17 August, “Body, Mind & Soul” responds to the business opportunities brought by the silver economy, with exhibitors launching a variety of products and services tailored for seniorsThe Beauty & Wellness Expo has introduced a new Polish pavilion this year, showcasing high-quality products such as caviar essence cream, pure natural essential oils, hair growth serums, and other products. The newly-established "Scentsation" zone focuses on perfumes and aromatherapy, featuring over 20 participating brandsThe Home Delights Expo's "Avenue of Delights" brand zone included more than 35 exhibitors, showcasing various lifestyle brandsThroughout the exhibitions, a series of highly popular and exciting events were held, including "Star Chef Cooking Demonstrations”, "Smart Bidding", and lucky drawsThe International Conference of the Modernization of Chinese Medicine and Health Products presented the latest professional information on Chinese medicine. The conference, themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", featured 21 prominent speakers, including experts from Hong Kong, mainland China, and overseas, sharing innovative achievements and development trends in the globalization of Chinese medicineTo learn more about the opinions of exhibitors and buyers, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.comHong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM)icmcm.hktdc.com Media EnquiriesOgilvy Public Relations:Rex CheukTel:(852) 5618 9908email: rex.cheuk@ogilvy.comLeanne PokTel:(852) 9379 9694 email: leanne.pok@ogilvy.comDaisy LeungTel:(852) 9275 7704email: daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs Department:Stanley SoTel:(852) 2584 4049email: stanley.hp.so@hktdc.orgSerena CheungTel:(852) 2584 4272email: serena.hm.cheung@hktdc.orgClayton LauwTel:(852) 2584 4472email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

CENTRESTAGE 10th anniversary set to dazzle in September
CENTRESTAGE 10th anniversary set to dazzle in September

- Some 260 brands from 24 countries and regions set to participate, a new high for the event, with the UK debuting as Partner Country to present works by leading British designers- Internationally acclaimed couturier Guo Pei will stage her first solo couture show in Hong Kong, unveiling 30 meticulously crafted pieces under the theme “Gilternity: An Everlasting Radiance”- Aligning with market trends, the fair will introduce a new Accessories Zone and will once again feature the Circular Fashion Zone to promote the development of sustainable fashion- The Fashion Hong Kong Runway Show will celebrate the creative journey of local brands; around 30 fashion shows will be staged during the fair – the highest number in the event’s historyHONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. The four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The  Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The 2025 CENTRESTAGE exhibition will feature some 260 brands from 24 countries and regions – the largest brand lineup in the event’s history.The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com.

斩获12金14银11铜 摘得大满贯！首程控股多家被投企业闪耀世界人形机器人运动会
斩获12金14银11铜 摘得大满贯！首程控股多家被投企业闪耀世界人形机器人运动会

香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 2025 年8月17 日，全球首个以人形机器人为核心参赛主体的大型综合性赛事——世界人形机器人运动会，在北京国家速滑馆"冰丝带"圆满落幕。本届运动会由北京市人民政府、中央广播电视总台、世界机器人合作组织、亚太机器人世界杯国际理事会等单位联合主办，集聚全球 280 支战队、500 余台机器人同台竞技，展现了具身智能机器人从技术突破走向场景应用的完整产业链条。在本次大会中，首程控股（0697.HK）作为深度产业推动者，多家被投企业集体亮相，参与多个重点项目并获得优异成绩，共计斩获37枚奖牌，其中包括12金14银11铜（包括各战队使用被投企业本体机器人参赛获奖情况）。与此同时，首程控股还在"冰丝带"外场打造了面向公众开放的"首程机器人科技体验店"，成为大会期间最受关注的互动展区之一。一、多家被投企业集结亮相本次赛事首程控股本次参展的多家企业涵盖了人形机器人本体、底层技术平台、零部件能力与具身智能生态的多个核心环节：宇树科技：在 2025 世界人形机器人运动会圆满落幕之际，宇树科技以出色的表现获得了四金，再次证明了其在全球人形机器人领域的技术领先地位。宇树科技的机器人在多个项目中表现卓越，分别夺得1500米、400米、100米障碍赛和 4×100米接力赛的金牌，展现了其在速度、灵活性和稳定性方面的强大实力。此外，在本届赛事中，宇树科技的机器人最高速度达到了 4.78m/s，这一成绩距离其内部测试的 5+m/s 还有一定差距，未来在速度和灵活性方面仍有巨大的提升空间。基于宇树科技 G1 硬件平台开发的独立参赛队伍也取得了不俗成绩，分别获得了1金1银1铜，进一步验证了宇树科技平台的广泛适应性与强大性能。北京人形机器人创新中心：在2025世界人形机器人运动会上，北京人形机器人创新中心展现了卓越的技术实力和广泛的场景适应能力，累计斩获2金6银2铜，成为本届赛事最具代表性的"全自主执行"技术方之一。在竞技赛部分，其打造的"天工 Ultra"机器人是 1500 米比赛中唯一全程自主奔跑、无遥控介入的选手，最终获得银牌；在 100 米项目中夺得金牌，在 400 米项目中拿下银牌与铜牌各一枚，并在 4×100 米接力赛中获得银牌，全面展示了其在复杂运动控制、节奏协调与导航算法方面的领先优势。在场景赛中，创新中心自主研发的天轶 2.0 机器人，凭借慧思开物"具身大脑+具身小脑"的智能协同体系，在"物料整理"项目中包揽金银牌，在"物料搬运"项目中斩获银牌与铜牌，并在"酒店迎宾服务技能竞赛"中收获银牌。这些项目均要求高度精细化操作与复杂场景适应能力，充分体现了其在"自主感知-智能决策-精准执行"完整闭环中的技术突破。作为本届赛事中"全自主"能力最突出的参赛单位，北京人形机器人创新中心不仅实现了从实验室走向复杂实战场景的关键跨越，也为具身智能的落地提供了极具参考价值的技术路径。松延动力：在本次运动会自由体操项目中，由松延动力自主研发的人形机器人"小顽童"以出色的平衡性、动态控制与节奏感，夺得冠军，展现出融合 AI 与动态模仿控制的高水平舞台表现力；博远智行 1 队采用松延动力机器人参赛，也在同一项目中荣获季军。在跳远项目中，松延动力的机器人再次发挥出色，赢得了冠军，展示了其在运动精度与协调性方面的强大能力。在单机舞蹈项目中，松延动力联合北京舞蹈学院组建代表队参赛，凭借对细节动作的精准复现和对舞台艺术的深度理解，最终斩获亚军，成为本届赛事"科技×艺术"融合的典范之一。松延动力此次在体操、跳远和舞蹈三个项目中斩获二金一银一铜，不仅证明了其机器人平台在高动态控制与 AI 动作生成领域的前沿实力，也进一步拓宽了人形机器人在文教娱乐、公共服务等方向的实际应用边界。银河通用：在首届世界人形机器人运动会中，银河通用 Galbot 队凭借全自主操作勇夺分拣技能竞技冠军。同时，来自中国矿业大学的北京北矿梦之队和北京建筑大学队等多支高校队伍也选择银河通用机器人参赛，均成功闯入复赛，其中矿大与北建大更是闯入决赛，最终分获亚军与第四名。至此，冠亚军由银河通用及采用银河通用机器人的队伍共同包揽，充分展现了银河通用技术的行业引领性与产品的通用性。星海图：在本次运动会中，星海图深度参与赛事生态构建，作为场景赛独家整机提供商，提前三周入驻实训场，为来自全国的 20 余支顶尖团队（包括北京林业大学、清华大学、北京航空航天大学等）提供总计 8 台人形机器人 R1 Pro、通用双臂移动操作平台 R1 Lite 及配套 VR 设备，并搭建开放软硬件平台，支撑参赛团队将创新算法从仿真环境部署至真实场景。场景赛覆盖的场景包括，酒店服务（床铺整理、迎宾行李搬运）、仓储中心（混合物料分拣）、医院场景（药品识别与补货）及工业场景（异物分拣与物料搬运）。走进冰丝带，就能看到星海图机器人和参赛选手们忙碌的身影。本次比赛中，来自北京航空航天大学的代表队采用星海图本体参与拆药分装场景赛，并成功获得季军，充分验证了星海图为开发者提供的具身智能开发平台的能力。加速进化：作为足球项目的核心技术支持方，加速进化为 3V3、5V5 等全部足球项目提供了竞技型人形机器人，承担了赛事中全部参赛队伍的机器人硬件支持与赛中技术保障。提供的机器人以高动态控制能力、抗干扰能力和场景适应性著称，展现了良好的对抗与战术执行能力。虽不作为直接参赛队伍名义参赛，但加速进化提供的技术平台承载了赛事中全部足球类奖牌的实现，是足球项目"幕后冠军"。二、科技体验走进生活，打造机器人产业"样板间"大会期间，首程控股在场馆外开设的"首程机器人科技体验店"也成为市民与游客热烈打卡的科技热点。店内集中展出200余款智能产品，涵盖智慧家居、儿童教育、AI娱乐、智能穿戴、户外运动等多个生活化场景。体验区共分为生态企业展示区、儿童互动区、医疗辅助区、AI音乐互动区等多个版块，成为让机器人"看得见、摸得着、用得上"的现实样本。首程控股执委、联席总裁叶芊在接受采访时表示："我们希望通过这次展示，让大家感受到机器人离生活越来越近。场馆内比的是专业能力，我们的体验店则通过贴近真实场景的互动设计，拉近机器人与大众的距离。"体验店内各展区的亮点纷呈：生态展示区以松延动力为代表，展示具备表情识别、人脸互动能力的拟人机器人，体现大模型与形态融合的前沿趋势；儿童体验区配置了汤姆猫、国际象棋机器人、AI 陪伴机器人和扫地机器人等设备，是全店人气最高区域；外骨骼与康复区设置跑步机、自行车等模拟设备，观众可实地体验机器人助力运动；智能穿戴区引入光粒品牌游泳眼镜，具备实时导航和运动数据采集能力；人机互动区展示了机器人自主演奏乐器及 AI 打击乐器、智能电吉他产品，深受观众欢迎；同时展出的还有 AI 中医问诊设备、具身底盘平台、机械臂抓取系统等，体现了机器人从"有脑、有脚、有手"的系统能力整合。三、首家正式体验店即将开业，全国推广启动在即本次"首程机器人科技体验店"为快闪形式试运营，但已获得极大市场关注。正式体验店预计将于"十一"期间在北京石景山-融石广场开业，后续还将布局至全国多个城市与重点场景（机场、高校、商圈等），形成连锁化、场景化的销售与体验网络。叶芊表示："我们将其定位为面向 C 端用户与城市生活空间的机器人应用窗口，也希望通过这类门店，持续验证市场需求、推动产品优化，帮助更多机器人企业走向商业化落地。"四、每一块奖牌，都是机器人走向未来的一小步人形机器人产业正在迎来从实验室走向真实场景的拐点。正如首程控股董事会办公室总经理康雨所指出："这场运动会，不仅比拼技术的高度，更关乎产业的温度--是一次让机器人真正走向应用、走进生活的生动演练。"未来，首程控股将持续依托"股权投资+资产运营"双轮驱动战略，携手被投企业与行业伙伴，推动机器人从看得见、摸得着的技术突破，走向用得上、可推广的现实应用，在教育、制造、城市运营、医疗康养等核心领域释放"下一代生产力"的真正价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

Shoucheng Portfolio Wins 37 Medals at Humanoid Robot Games
Shoucheng Portfolio Wins 37 Medals at Humanoid Robot Games

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - On August 17, 2025, the inaugural World Humanoid Robot Games—an international event centered on humanoid robots—concluded successfully at the National Speed Skating Oval in Beijing, also known as the “Ice Ribbon.”Co-hosted by the Beijing Municipal Government, China Media Group, the World Robot Cooperation Organization, and the Asia-Pacific RoboCup Council, the Games gathered 280 teams and over 500 robots from around the globe to compete across 26 disciplines, showcasing the full industrial chain from technological breakthroughs to real-world applications in embodied intelligence.As a key industrial accelerator, Shoucheng Holdings (0697.HK) saw several of its portfolio companies participate in major events, collectively winning 37 medals (12 gold, 14 silver, and 11 bronze), including awards where teams utilized robots built by Shoucheng’s portfolio firms. Simultaneously, Shoucheng launched the "Shoucheng Robot Tech Experience Store" adjacent to the venue, which became one of the most visited tech exhibits of the event.Highlights from Portfolio Companies:Unitree Robotics captured 4 gold medals and achieved a top speed of 4.78 m/s; G1-based teams earned an additional 1 gold, 1 silver, and 1 bronze;Beijing Humanoid Robot Innovation Center won 2 gold, 6 silver, and 2 bronze, representing the most advanced “fully autonomous execution” capabilities;Noetix Robotics earned 2 gold, 1 silver, and 1 bronze in gymnastics, long jump, and dance events, becoming a standout in “Tech × Art” integration;Galbot (by Galbot Technologies) secured the autonomous sorting championship and supported university teams that swept the podium;Galaxea-AI served as exclusive hardware provider in scene-based competitions and enabled a third-place finish by Beihang University;Booster Robotics powered all 3V3 and 5V5 football events, providing robot hardware and technical support, and was deemed the “backstage champion.”Robot Tech Experience Store: Bringing Innovation to the EverydayDuring the event, Shoucheng launched a pop-up “Robot Tech Experience Store,” featuring over 200 smart products across home, education, entertainment, healthcare, and wearables. The official store will open during China’s National Day Golden Week in October 2025 at Fusion Stone Plaza, Beijing, with nationwide expansion plans into airports, campuses, and commercial hubs.As Shoucheng’s Executive Director and Co-President Ye Qian stated: “Through interactive and relatable scenarios, we want the public to feel that robots are no longer distant technologies—they’re becoming part of daily life.”From Lab to Market: Accelerating the New Productive ForceWith a dual strategy of equity investment and asset operations, Shoucheng Holdings will continue to drive commercialization of humanoid and embodied robots in education, manufacturing, healthcare, and smart city operations, unlocking the full potential of the next-generation productivity paradigm.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

中国生物制药（1177.HK）公布2025中期业绩
中国生物制药（1177.HK）公布2025中期业绩

重点成果- 期内，集团共有2个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因子VIIa N01）。- 2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日，集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂，目前已获批9个适应症，另有3个适应症处于上市申请阶段。此外，安罗替尼还有多项新适应症处于III期临床研究阶段，包括一线非鳞状非小细胞肺癌、一线胰腺癌等，预计将在未来两年逐步递交上市申请。- 2023-2024年，集团共有5款肿瘤领域的国家1类创新药获批上市，分别为：亿立舒（艾贝格司亭α注射液）、安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和安方宁（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯（贝伐珠单抗注射液）、得利妥（利妥昔单抗注射液）、赛妥（注射用曲妥珠单抗）和帕乐坦（帕妥珠单抗注射液）。该等产品在2025年上半年快速放量，成为集团收入增长的重要贡献品种。- 拉尼兰诺（泛PPAR激动剂）是一种口服小分子药物，用于治疗代谢功能障碍相关脂肪性肝炎（MASH），目前正在全球开展III期临床试验，已完成全部受试者入组。2023年7月，拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物，有望填补中国市场空白。- 天晴速畅（吸入用布地奈德混悬液）是中国首款获批上市的布地奈德雾化剂型仿制药，打破了国内市场长期被原研垄断的局面，为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长10.7%至约175.7亿元（人民币，下同）。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元，同比增长约140.2%，基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利（非香港财务报告准则指标）约30.9亿元，同比增长约101.1%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元，理财管理产品总额约92.9亿元，资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙（2024上半年：3港仙）。销售：研发创新动能强劲，多领域销售成果持续放量集团一直以来重视研发，持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。期内，抗肿瘤用药之收入同比增加24.9%，达约66.9亿元，占集团收入约38.1%。外科／镇痛用药之收入同比增加20.2%，达约31.1亿元，占集团收入约17.7%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床，EGFR/cMet双抗ADC TQB6411 I期临床正在入组，两款产品进度均位于中国前列；深度布局乳腺癌三大亚型， CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法，HER2双抗ADC TQB2102较DS-8201潜在安全性优效，多个适应症正在同步拓展，其中三项乳腺癌III期快速推进；系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿，LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快，且目前临床数据展示出了极大潜力。于外科╱镇痛领域，集团持续聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求。期内，集团推动泽普思销售额持续快速增长，而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时，2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势，有望成为该领域新的增长动力。研发：全力以赴推动创新产品开发，加大研发的资金投入于报告期内，集团共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因数VIIa N01）。2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。一直以来，集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的资金投入。截至二零二五年六月三十日止六个月，研究与开发成本约人民币318,756万元，占本集团收入约18.1%，连同已资本化的研发总开支出在内，约95.7%已计入损益表中。展望：深化创新与国际化布局，加速构建全球医药创新竞争力当前，中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下，我国生物医药创新能力显著提升，创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能，更在全球市场逐步崭露头角，日益获得广泛认可，已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业，集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域，专注创新，服务病患，目标成为全球领先的制药企业。集团深耕中国市场，同时将战略视野投向全球市场，以国际化加速创新发展。同时，集团大力推进全球战略合作布局，通过商务拓展（BD）、战略收购等多元合作路径，快速充实创新管线储备，强化核心技术平台。2025年7月，集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台，包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台（LM-Abs™），新一代抗体偶联药物平台（LM-ADC™）、以及免疫细胞衔接器平台（LM-TCE™）。此次收购将进一步增强集团的创新研发能力，加速集团的创新业务增长。此外，礼新医药卓越高效的研发团队将加入集团，进一步强化集团的创新研发人才储备，为持续产出高水平创新成果提供保障，助力创新生态的长远发展。未来，本集团将继续聚焦创新，提升四大治疗领域的研发效率与质量，加快国际化步伐，力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Sino Biopharm (1177.HK) Announces 2025 Interim Results
Sino Biopharm (1177.HK) Announces 2025 Interim Results

Development Highlights- During the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.- As of 30 June 2025, the Group had a total of 37 innovative drug candidates in the field of oncology, 7 innovative drug candidates related to liver/metabolic diseases, 13 innovative drug candidates related to the respiratory, and 6 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 2 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 11 innovative oncology drug candidates, 1 innovative liver/metabolic diseases drug candidate, 3 innovative respiratory system drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. In addition, the Group had a total of 13 biosimilar or generic drug oncology candidates, 6 additional biosimilar or generic liver/metabolic diseases drug candidates, 12 biosimilar or generic respiratory system drug candidates, and 6 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. It has been approved for nine indications, and three other indications are currently in the marketing application stage. In addition, Anlotinib has a number of new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2024, the Group obtained approval for and launched a total of five national category 1 innovative oncology drugs, namely, Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets). It also obtained approval for and launched 4 oncology biosimilars, including Anbesi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab Injection), and Paletan (Pertuzumab Injection). The sales volume of these products accelerated rapidly in the first half of 2025, and they have become important contributors to the Group’s revenue growth.- Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and enrollment of the patients in the global main cohort has been completed. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national VBP. The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP.- Zepolas/Debaian (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. By upgrading the dosage form, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2025 (the “Period”).During the Period, the Group recorded revenue of approximately RMB17.57 billion, a year-on-year increase of approximately 10.7%. Profit attributable to owners of the parent from continuing operations as reported was approximately RMB3.39 billion, a year-on-year increase of approximately 140.2%. Earnings per share attributable to owners of the parent were approximately RMB18.82 cents. The significant year-over-year increase in profit attributable to owners of the parent from continuing operations was mainly driven by the notable growth in revenue and significant increase in dividend income and fair value gain on investments during the Period. Underlying profit attributable to owners of the parent (non-HKFRSs measure) was approximately RMB3.09 billion, a YOY increase of approximately 101.1%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB11.1 billion, bank deposits classified as non-current assets of approximately RMB10.1 billion, and wealth management products of approximately RMB9.29 billion in total, and total fund reserves amounting to approximately RMB30.49 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK5 cents per share (1H2024: HK3 cents).Sales: Strong momentum in R&D innovation with volume growth across multiple fieldsAlways placing utmost importance on research and development (“R&D”), the Group has consistently increased investments to enhance R&D quality and efficiency, which has led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. During the Period, sales of oncology drugs increased by 24.9% year-on-year to approximately RMB6.69 billion, accounting for approximately 38.1% of the Group's revenue. Sales of surgical/analgesic medications increased by 20.2% year-on-year to approximately RMB3.11 billion, accounting for approximately 17.7% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. The EGFR/cMet bispecific antibody TQB2922 is about to initiate a Phase III clinical trial for second-line NSCLC, while the EGFR/cMet bispecific antibody ADC TQB6411 is currently enrolling patients for its Phase I trial, with both products progressing at the forefront in China. Also, the Group is deeply invested in the three major subtypes of breast cancer. The CDK2/4/6 inhibitor “Culmerciclib Capsule (TQB3616)” has the potential to become a best-in-class (BIC) therapy for HR+/HER2- breast cancer. The HER2 bispecific ADC TQB2102 demonstrates potentially superior safety compared to DS-8201, with multiple indications being explored simultaneously, including three breast cancer Phase III trials advancing rapidly. Additionally, the Group has systematically targeted key gastrointestinal cancers such as colorectal, gastric, pancreatic, and liver cancers. LM-108 (CCR8 monoclonal antibody) and TQB2868 (PD-1/TGF-β bifunctional fusion protein) are progressing at the fastest pace globally, with current clinical data showing significant potential.In the field of surgery/analgesia, the Group continuously focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. During the Period, the Group drove the sustained rapid sales growth of Zepolas, and the second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. Meanwhile, Putanning, which was approved in May 2025, is expected to become a new growth driver in this field due to its strengths, such as long-acting analgesia and excellent safety.R&D: Fully Committed to Advancing Innovative Product Development with Enhanced R&D InvestmentDuring the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.The Group has always placed the utmost importance on R&D, continuously improving its R&D capabilities and speed. It considers R&D the foundation for its sustainable development and has continuously increased its investment in R&D. For the six months ended 30 June 2025, R&D costs amounted to approximately RMB3,187.56 million, representing approximately 18.1% of the Group’s revenue. Including capitalised R&D expenditure, approximately 95.7% was recognised in the statement of profit or loss.Prospect: Deepening Innovation and Global Expansion to Accelerate the Building of Global Pharmaceutical Innovation CompetitivenessChina’s pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country’s biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the “passive mover” towards the “paralleled player,” or even the “market leader” on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognized and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas – oncology, liver/metabolic diseases, respiratory diseases, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. In the meantime, the Group is vigorously promoting its global strategic collaboration deployments through diversified approaches of collaborations such as business development (BD), strategic acquisitions, etc. In July 2025, the Group announced the full acquisition of LaNova Medicines. LaNova Medicines boasts world-leading antibody discovery and ADC technology platforms, including the Tumor Microenvironment Specific Antibody Development Platform (LM-TME™), the Targeted Antibody Discovery Platform (LM-Abs™), the New Generation ADC Platform (LM-ADC™), and the T-cell Engager Platform (LM-TCE™). The acquisition will further enhance the Group's innovative R&D capabilities and accelerate the growth of the Group's innovative business. In addition, the LaNova Medicines’ outstanding and efficient R&D team will join the Group to further strengthen its innovation and R&D talent pool, ensuring the sustained delivery of high-quality innovation outcomes, and supporting the long term development of the Group’s innovation ecosystem.Looking ahead, the Group will remain focused on innovation, while enhancing R&D efficiency and quality across its four major therapeutic areas. The Group will also accelerate its progress of internationalization, thereby striving for rapid business expansion alongside steady performance improvement.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver/Metabolic Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for seven consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada
Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

斩获12金14银11铜 摘得大满贯！首程控股多家被投企业闪耀世界人形机器人运动会
斩获12金14银11铜 摘得大满贯！首程控股多家被投企业闪耀世界人形机器人运动会

香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 2025 年8月17 日，全球首个以人形机器人为核心参赛主体的大型综合性赛事——世界人形机器人运动会，在北京国家速滑馆"冰丝带"圆满落幕。本届运动会由北京市人民政府、中央广播电视总台、世界机器人合作组织、亚太机器人世界杯国际理事会等单位联合主办，集聚全球 280 支战队、500 余台机器人同台竞技，展现了具身智能机器人从技术突破走向场景应用的完整产业链条。在本次大会中，首程控股（0697.HK）作为深度产业推动者，多家被投企业集体亮相，参与多个重点项目并获得优异成绩，共计斩获37枚奖牌，其中包括12金14银11铜（包括各战队使用被投企业本体机器人参赛获奖情况）。与此同时，首程控股还在"冰丝带"外场打造了面向公众开放的"首程机器人科技体验店"，成为大会期间最受关注的互动展区之一。一、多家被投企业集结亮相本次赛事首程控股本次参展的多家企业涵盖了人形机器人本体、底层技术平台、零部件能力与具身智能生态的多个核心环节：宇树科技：在 2025 世界人形机器人运动会圆满落幕之际，宇树科技以出色的表现获得了四金，再次证明了其在全球人形机器人领域的技术领先地位。宇树科技的机器人在多个项目中表现卓越，分别夺得1500米、400米、100米障碍赛和 4×100米接力赛的金牌，展现了其在速度、灵活性和稳定性方面的强大实力。此外，在本届赛事中，宇树科技的机器人最高速度达到了 4.78m/s，这一成绩距离其内部测试的 5+m/s 还有一定差距，未来在速度和灵活性方面仍有巨大的提升空间。基于宇树科技 G1 硬件平台开发的独立参赛队伍也取得了不俗成绩，分别获得了1金1银1铜，进一步验证了宇树科技平台的广泛适应性与强大性能。北京人形机器人创新中心：在2025世界人形机器人运动会上，北京人形机器人创新中心展现了卓越的技术实力和广泛的场景适应能力，累计斩获2金6银2铜，成为本届赛事最具代表性的"全自主执行"技术方之一。在竞技赛部分，其打造的"天工 Ultra"机器人是 1500 米比赛中唯一全程自主奔跑、无遥控介入的选手，最终获得银牌；在 100 米项目中夺得金牌，在 400 米项目中拿下银牌与铜牌各一枚，并在 4×100 米接力赛中获得银牌，全面展示了其在复杂运动控制、节奏协调与导航算法方面的领先优势。在场景赛中，创新中心自主研发的天轶 2.0 机器人，凭借慧思开物"具身大脑+具身小脑"的智能协同体系，在"物料整理"项目中包揽金银牌，在"物料搬运"项目中斩获银牌与铜牌，并在"酒店迎宾服务技能竞赛"中收获银牌。这些项目均要求高度精细化操作与复杂场景适应能力，充分体现了其在"自主感知-智能决策-精准执行"完整闭环中的技术突破。作为本届赛事中"全自主"能力最突出的参赛单位，北京人形机器人创新中心不仅实现了从实验室走向复杂实战场景的关键跨越，也为具身智能的落地提供了极具参考价值的技术路径。松延动力：在本次运动会自由体操项目中，由松延动力自主研发的人形机器人"小顽童"以出色的平衡性、动态控制与节奏感，夺得冠军，展现出融合 AI 与动态模仿控制的高水平舞台表现力；博远智行 1 队采用松延动力机器人参赛，也在同一项目中荣获季军。在跳远项目中，松延动力的机器人再次发挥出色，赢得了冠军，展示了其在运动精度与协调性方面的强大能力。在单机舞蹈项目中，松延动力联合北京舞蹈学院组建代表队参赛，凭借对细节动作的精准复现和对舞台艺术的深度理解，最终斩获亚军，成为本届赛事"科技×艺术"融合的典范之一。松延动力此次在体操、跳远和舞蹈三个项目中斩获二金一银一铜，不仅证明了其机器人平台在高动态控制与 AI 动作生成领域的前沿实力，也进一步拓宽了人形机器人在文教娱乐、公共服务等方向的实际应用边界。银河通用：在首届世界人形机器人运动会中，银河通用 Galbot 队凭借全自主操作勇夺分拣技能竞技冠军。同时，来自中国矿业大学的北京北矿梦之队和北京建筑大学队等多支高校队伍也选择银河通用机器人参赛，均成功闯入复赛，其中矿大与北建大更是闯入决赛，最终分获亚军与第四名。至此，冠亚军由银河通用及采用银河通用机器人的队伍共同包揽，充分展现了银河通用技术的行业引领性与产品的通用性。星海图：在本次运动会中，星海图深度参与赛事生态构建，作为场景赛独家整机提供商，提前三周入驻实训场，为来自全国的 20 余支顶尖团队（包括北京林业大学、清华大学、北京航空航天大学等）提供总计 8 台人形机器人 R1 Pro、通用双臂移动操作平台 R1 Lite 及配套 VR 设备，并搭建开放软硬件平台，支撑参赛团队将创新算法从仿真环境部署至真实场景。场景赛覆盖的场景包括，酒店服务（床铺整理、迎宾行李搬运）、仓储中心（混合物料分拣）、医院场景（药品识别与补货）及工业场景（异物分拣与物料搬运）。走进冰丝带，就能看到星海图机器人和参赛选手们忙碌的身影。本次比赛中，来自北京航空航天大学的代表队采用星海图本体参与拆药分装场景赛，并成功获得季军，充分验证了星海图为开发者提供的具身智能开发平台的能力。加速进化：作为足球项目的核心技术支持方，加速进化为 3V3、5V5 等全部足球项目提供了竞技型人形机器人，承担了赛事中全部参赛队伍的机器人硬件支持与赛中技术保障。提供的机器人以高动态控制能力、抗干扰能力和场景适应性著称，展现了良好的对抗与战术执行能力。虽不作为直接参赛队伍名义参赛，但加速进化提供的技术平台承载了赛事中全部足球类奖牌的实现，是足球项目"幕后冠军"。二、科技体验走进生活，打造机器人产业"样板间"大会期间，首程控股在场馆外开设的"首程机器人科技体验店"也成为市民与游客热烈打卡的科技热点。店内集中展出200余款智能产品，涵盖智慧家居、儿童教育、AI娱乐、智能穿戴、户外运动等多个生活化场景。体验区共分为生态企业展示区、儿童互动区、医疗辅助区、AI音乐互动区等多个版块，成为让机器人"看得见、摸得着、用得上"的现实样本。首程控股执委、联席总裁叶芊在接受采访时表示："我们希望通过这次展示，让大家感受到机器人离生活越来越近。场馆内比的是专业能力，我们的体验店则通过贴近真实场景的互动设计，拉近机器人与大众的距离。"体验店内各展区的亮点纷呈：生态展示区以松延动力为代表，展示具备表情识别、人脸互动能力的拟人机器人，体现大模型与形态融合的前沿趋势；儿童体验区配置了汤姆猫、国际象棋机器人、AI 陪伴机器人和扫地机器人等设备，是全店人气最高区域；外骨骼与康复区设置跑步机、自行车等模拟设备，观众可实地体验机器人助力运动；智能穿戴区引入光粒品牌游泳眼镜，具备实时导航和运动数据采集能力；人机互动区展示了机器人自主演奏乐器及 AI 打击乐器、智能电吉他产品，深受观众欢迎；同时展出的还有 AI 中医问诊设备、具身底盘平台、机械臂抓取系统等，体现了机器人从"有脑、有脚、有手"的系统能力整合。三、首家正式体验店即将开业，全国推广启动在即本次"首程机器人科技体验店"为快闪形式试运营，但已获得极大市场关注。正式体验店预计将于"十一"期间在北京石景山-融石广场开业，后续还将布局至全国多个城市与重点场景（机场、高校、商圈等），形成连锁化、场景化的销售与体验网络。叶芊表示："我们将其定位为面向 C 端用户与城市生活空间的机器人应用窗口，也希望通过这类门店，持续验证市场需求、推动产品优化，帮助更多机器人企业走向商业化落地。"四、每一块奖牌，都是机器人走向未来的一小步人形机器人产业正在迎来从实验室走向真实场景的拐点。正如首程控股董事会办公室总经理康雨所指出："这场运动会，不仅比拼技术的高度，更关乎产业的温度--是一次让机器人真正走向应用、走进生活的生动演练。"未来，首程控股将持续依托"股权投资+资产运营"双轮驱动战略，携手被投企业与行业伙伴，推动机器人从看得见、摸得着的技术突破，走向用得上、可推广的现实应用，在教育、制造、城市运营、医疗康养等核心领域释放"下一代生产力"的真正价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

艾曲莫德入选《2025 ACG临床指南：成人溃疡性结肠炎》，获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
艾曲莫德入选《2025 ACG临床指南：成人溃疡性结肠炎》，获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗

香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，旗下创新药艾曲莫德（VELSIPITY(R)，etrasimod）被纳入《2025 ACG 临床指南：成人溃疡性结肠炎》（下称"新版指南"），并获得强烈推荐用于中重度活动性溃疡性溃疡性结肠炎（UC）患者的诱导缓解及维持缓解治疗（中等质量证据）。新版指南同时建议，对于已通过鞘氨醇-1-磷酸（S1P）受体调节剂实现诱导缓解的患者，继续使用艾曲莫德以维持缓解（强烈推荐，中等质量证据）。这一重要进展不仅体现了国际权威医学指南对艾曲莫德临床价值的高度认可，也进一步彰显了其在满足UC患者未被满足的治疗需求方面的潜力，为全球UC患者提供新的治疗选择。此次新版指南由美国胃肠病学会（American College of Gastroenterology，ACG）制定，基于近五年最新循证医学证据，系统总结了UC治疗及并发症预防的新方法与新进展，为临床医生提供规范、科学的管理参考，以更好地应对不同程度的UC患者治疗需求。新版指南指出，艾曲莫德作为新一代高选择性S1P受体调节剂，通过将活化的淋巴细胞滞留于淋巴结中，减少其在肠道中的浸润，从而降低局部炎症反应，并伴随外周循环淋巴细胞计数下降。艾曲莫德ELEVATE UC III 期注册研究（ELEVATE UC 52和ELEVATE UC 12）这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，分别在第12周和第52周显著改善临床缓解率，并实现持久的内镜下深度黏膜愈合。值得注意的是，研究中100%的临床缓解均为无激素缓解，安全性良好，与既往研究结果一致。指南也特意强调了与其他现有治疗不同的是，艾曲莫德 ELEVATE UC III 期注册研究中纳入了溃疡性直肠炎，且证实了在此类人群中显著提升了临床缓解率（治疗12周时，43.2% vs 13.6%, p＜0.001）。此前，艾曲莫德还被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。艾曲莫德亚太临床试验牵头研究者、世界胃肠病学会司库、亚太消化病学会副主席、中华医学会第十届消化病学分会副主任委员、中国人民解放军第四军医大学附属西京医院吴开春教授表示："新版指南进一步明确，'实现内镜黏膜愈合以达成持续无激素缓解和避免住院手术'是中重度溃疡性结肠炎治疗的核心目标，这不仅关系到疾病的长期安全管理，也与改善患者生活质量息息相关。此次指南中，艾曲莫德被强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，标志着其临床价值获得了国际权威学术机构的高度认可，也为临床实践提供了全新的治疗选择。"云顶新耀首席执行官罗永庆表示："艾曲莫德此次获新版指南强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，充分体现了其卓越的临床疗效和良好安全性，进一步确立了其作为一线治疗新选择的重要地位。新版指南明确将实现内镜黏膜愈合作为治疗中重度活动性溃疡性结肠炎的核心目标，印证了黏膜愈合为国内外指南一致认定的重要终点，可显著降低疾病复发、住院、结直肠切除及结直肠癌风险。值得一提的是，指南特别强调了艾曲莫德在溃疡性直肠炎患者中同样可显著提升临床缓解率。在亚洲，溃疡性结肠炎患者人数持续上升，以中国为例，2024年中国的溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人，现有临床治疗选择有限，迫切需要兼顾疗效、安全性与便利性的创新方案。我们将加速艾曲莫德的商业化进程，助力更多患者长期维持安全有效的疾病缓解，并提升生活质量。"作为云顶新耀在自身免疫疾病领域布局的核心创新产品，艾曲莫德（维适平(R)）的新药上市申请已于2024年12月获中国国家药品监督管理局正式受理，预计今年年底或明年年初获批。艾曲莫德已在新加坡、中国澳门和中国香港获批，其新药上市许可申请也已在韩国和中国台湾地区获正式受理。艾曲莫德已被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（2024年），在大湾区先行使用，成为云顶新耀第三款商业化新药。云顶新耀已于2025年3月启动艾曲莫德在嘉善工厂的本地化生产建设项目，支持其在大中华区及其他亚洲市场的供应及商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元

业绩亮点：- 收入达83.6百万美元，同比增长5.9%。- 销量达919,000件，其中779,000件为自有产品，同比增长8.6%。- 公司拥有人应占利润同比上升5.1%至19.8百万美元。- 核心经营利润达15.1百万美元，同比增长11.4%。- 为庆祝集团成立25周年，董事会宣派特别股息每股15港仙。- 财务状况稳健，截至2025年6月30日，现金及银行结余达237.1百万美元，支持潜在收购及新生产设施建设。- 优质产品获全球广泛认可，带动亚太地区市场收入按年增长14.0%，欧洲、中东及非洲市场增长17.0%，及美国市场增长20.0%。- 于上半年收购一家台湾经销商，并计划下半年于比利时及荷兰设立直销团队，进一步加强在亚太地区及欧洲、中东及非洲市场的影响力。- 集团善用全球商业化专长及庞大销售网络，与医疗器械同业建立战略合作，藉此丰富产品组合，并透过交叉销售创造额外收入。香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球医疗器械制造公司业聚医疗集团控股有限公司（"业聚医疗"或"集团"；股份代号：6929）今天宣布截至2025年6月30日止六个月("报告期")的中期业绩。尽管宏观经济环境未见明朗，集团的收入及纯利仍双双录得增长。美国市场增长强劲，加上亚太地区及欧洲、中东与非洲地区新兴市场的持续贡献，推动集团收入达到83.6百万美元，较去年同期上升5.9%。核心经营利润（自本公司拥有人应占利润撇除以股份为基础的薪酬开支、与税务亏损相关的递延税项资产的税务抵免净额及融资收入╱成本）为15.1百万美元，同比增长11.4%。公司拥有人应占利润同比上升5.1%至19.8百万美元。每股基本盈利为2.40美仙（2024年上半年：2.28美仙）。截至2025年6月30日，集团财务状况保持稳健，现金及银行结余达237.1百万美元。鉴于集团的财务状况稳健，以及为庆祝成立25周年，董事会议决宣派特别现金股息每股普通股15港仙，彰显集团致力为股东创造价值。连同截至2024年12月31日止年度之末期股息每股10港仙（已于2025年6月16日派付），股东于2025年合共获派股息每股25港仙。业聚医疗董事长、执行董事兼首席执行官钱永勋先生表示："过去25年，我们持续投资于创新及全球商业化能力，除了为业聚医疗建立了声誉，也助我们在不同的经济周期中破浪前行。尽管2025年上半年面临宏观经济及地缘政治的双重挑战，我们的全球布局仍展现韧性。美国市场增长印证了市场对我们的优质产品需求殷切，而我们亦透过庞大的销售网络，成功把握了亚太地区及欧洲、非洲及中东地区的增长机遇。我们将继续透过直销市场覆盖、卓越的销售支援、对创新的投入，以及全面的PCI和PTA产品组合提升品牌价值，从而强化竞争优势，为医生及患者提供更安全有效治疗方案的同时，也为股东创造长远回报。"全球销售网络及合作伙伴关系推动收入增长业聚医疗已建立覆盖逾70个国家及地区的销售网络，在13个地区设立直销团队并建立全球经销商网络，成为把握各地机遇、回应当地需求的重要一环。期内，受惠于印尼市场增长，以及Scoreflex TRIO 在新加坡及马来西亚获更广泛采用，亚太地区收入同比上升14.0%至27.3百万美元。欧洲、中东及非洲市场方面，德国、法国及西班牙等直销市场及包括英国、斯洛伐克及捷克共和国在内的分销市场的自有球囊类产品销售表现强劲，带动该区收入上升17.0%至22.4百万美元。尽管受关税因素影响，美国市场收入仍同比上升20.0%至8.0百万美元，主要受冠脉的普通及刻痕球囊，包括高价产品Scoreflex NC球囊，以及外周球囊销量显著上升所推动。而日本及中国境内市场的收入分别为16.1百万美元及9.7百万美元。凭借其广受认可的全球商业化能力，集团与立志走向国际巿场的同业合作，藉此丰富产品组合并开拓额外收入来源。继去年与深圳开立生物医疗科技股份有限公司成功展开合作，在香港及澳门分销血管内超声产品后，集团与该伙伴再度签订独家分销协议，在新加坡及马来西亚分销相关产品。至目前为止，合作范围已进一步扩展至集团旗下位于欧洲的4个直销市场，包括法国、德国、西班牙及瑞士，及其他6个分销市场。性能主导的多元化创新产品组合，提升市场差异化水平截至2025年6月30日，业聚医疗在全球主要司法管辖区拥有逾250项授权专利及已公布专利申请，及逾55款获批产品。期内，集团产品注册及临床试验继续取得进展，包括：- Sapphire 3的美国临床试验进展顺利，预期于2025年第四季度完成病人入组，以支持该产品的FDA纳入CTO适应症，从而与市场上其他传统半顺应性球囊形成差异化；- JADE PLUS及Teleport Glide获得CE标志、Teleport Glide及Scoreflex QUAD获得PMDA批准、COREPASS模组化微导管获得FDA批准、导引导管获得国家药监局批准；- 就Scoreflex TRIO、Sapphire ULTRA、Sapphire NC ULTRA、Sapphire NC 24、JADE PLUS、Teleport XT及Teleport Glide向国家药监局提交注册申请，并就Vascuaid抽吸导管及大管腔延长导管向PMDA提交注册申请。集团拥有庞大的产品管线。在冠状动脉领域，Sapphire PTX紫杉醇药物涂层球囊大约于2025年底在日本展开临床研究；外周方面，JADE Score球囊则预期于2026年向PMDA提交注册申请。合资企业业聚培福在中国境内展开的TricValve临床试验亦取得重大进展，参与医院数量上升，加快了病人入组进度。此外，业聚培福亦正透过"港澳注册药品及医疗器械进入大湾区计划"，积极推动大湾区各大医院采用TricValve。TricValve于2025年7月完成首次在中国境内进行的商业化植入手术，达到重要的里程碑。多区域生产基地缓解地缘政治风险截至2025年6月30日，业聚医疗于中国深圳、荷兰荷佛拉肯，以及德国莱茵河畔魏尔设有生产基地，总年产能约为210万件球囊及支架。自2023年底收购eucatech AG以来，集团已投入资源恢复其生产能力，期内产量逐步提升，以供应销售及临床注册所需产品。2025年8月，集团完成位于中国杭州、旗下最大研发及生产基地的主体结构建设，装修工程预期于下半年展开。该基地计划于2027年投产，届时将新增年产能240万件。钱先生总结说："有见于新兴市场的强劲势头、自研产品陆续成功推出巿场，以及已建立的战略合作，我们对2025年下半年前景保持乐观。除了亚太地区及欧洲、中东及非洲将继续担当主要的增长引擎，我们亦计划将部分市场由分销模式转为直销模式，以强化当地营收能力及市场渗透。欧洲市场将透过于比利时及荷兰设立直销团队加强市场影响力；日本市场则藉新产品上市重拾增长动力；而在中国境内市场，我们则把握政策支持，扩大产品覆盖并加速商业化进程。随着关税争端缓和，美国市场的产品交付亦有望加快。凭借业聚医疗多元化的产品组合、稳健的财务状况及规模经济效益，我们具备优势构建具韧性及竞争力的业务体系，为持份者创造可持续的价值。"关于业聚医疗集团控股有限公司业聚医疗是一家全球医疗器械制造公司，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。本集团总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至结构性心脏病领域。凭借拥有逾20年产品开发经验的内部研发团队，本集团已开发出世界领先的专有技术。如需了解更多详情，请访问集团官网：https://orbusneich.com/ Copyright 2025 亚太商讯 via SeaPRwire.com.

广发证券荣膺国家数据管理能力成熟度（DCMM）最高等级认证
广发证券荣膺国家数据管理能力成熟度（DCMM）最高等级认证

广州，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 近日，中国电子信息行业联合会公布最新一批获颁数据管理能力成熟度（简称"DCMM"）等级证书企业名单，广发证券获评最高等级五级（优化级）认证，成为行业首家获评最高等级的证券公司，标志着公司在数据管理和应用方面达到国内领先水平，为行业数据管理能力建设树立标杆。《数据管理能力成熟度评估模型》（GB/T 36073-2018）是我国数据管理领域正式发布的首个国家标准。该认证从数据战略、数据治理、数据架构、数据应用等多个维度，全面评估企业的数据管理能力。其中，五级（优化级）作为最高等级，标志着企业的数据管理已形成行业最佳实践，具备强大的示范引领作用。一直以来，广发证券高度重视数据管理能力的建设与提升，将数据视为企业核心资产。公司构建了"战略引领、全员参与、跨部门协同、全生命周期管理"的数据管理体系。通过制定清晰的数据战略规划，完善数据治理组织架构与制度流程，强化数据安全与合规管理，持续提升数据质量与应用效能，公司实现了数据管理从"规范"到"优化"的跨越式发展，为业务创新、客户服务升级及风险管理提供了强有力的数据支撑。广发证券副总经理、首席信息官辛治运表示："公司将以此次获得DCMM五级认证为新的起点，持续深化数据管理能力建设，进一步完善数据治理长效机制，推动数据技术与业务场景的深度融合，并以此为契机，不断提升服务实体经济的质效，为证券行业的数据管理创新与发展贡献更多力量。" Copyright 2025 亚太商讯 via SeaPRwire.com.

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the “Updated Guidelines”). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence.This milestone underscores the high level of recognition from an internationally respected clinical guideline for the therapeutic value of etrasimod and highlights its potential to address the significant unmet medical needs of UC patients, offering a new treatment option worldwide.The updated guidelines were developed by the American College of Gastroenterology (ACG) including the latest evidence from the past five years. They provide a comprehensive summary of new approaches and advances in the treatment and prevention of complications in UC, with the goal of offering clinicians standardized and evidence-based recommendations to better manage patients with varying degrees of disease severity.The updated guidelines note that, etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active UC. The S1P 1 receptor modulation regulates the trafficking of specific lymphocyte subsets out of the lymph nodes, leaving fewer peripheral immune cells available to traffic to sites of inflammation.The updated guidelines also reference the Phase III ELEVATE UC clinical study for etrasimod (ELEVATE UC 52 and ELEVATE UC 12). Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod. Etrasimod has been included in the AGA Living Clinical Practice Guideline on the pharmacological management of moderate-to-severe UC as one of the higher-efficacy medications suggested for first-line use in advanced therapy-naïve patients.Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial said “The updated guidelines further emphasize that achieving endoscopic mucosal healing to enable sustained, steroid-free remission is a core treatment goal for patients. This is not only critical for the long-term and safe management of the disease but is also closely tied to improving patients’ quality of life. The strong recommendation of etrasimod for both induction and maintenance therapy in this population reflects the high level of recognition from an internationally authoritative medical authority.”“The inclusion of etrasimod in the 2025 American College of Gastroenterology (ACG) Clinical Guideline for Adult Ulcerative Colitis, with a strong recommendation, is a clear recognition of its clinical efficacy and favorable safety profile. Mucosal healing is a recognized treatment goal in both domestic and international clinical guidelines for UC. Achieving mucosal healing at an early stage can significantly reduce the risk of disease relapse, hospitalization, colectomy, and the development of colorectal cancer.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “In Asia, the number of UC patients continues to rise, while treatment options remain limited, highlighting an urgent need for innovative therapies that balance efficacy, safety, and convenience. In China alone, the UC patient population was estimated at approximately 800,000 in 2024 and is projected to reach 1 million by 2030, placing an increasing burden on the healthcare system.”As a key innovative asset in Everest Medicines’ autoimmune disease portfolio, etrasimod’s inclusion in the clinical guidelines underscores its global therapeutic potential as a new treatment option for UC patients across Asia, including in China. We remain committed to accelerating the regulatory approval process for etrasimod in Mainland China, South Korea, and other Asian markets to enhance patient access and help more individuals achieve higher-quality, longer-lasting disease remission.”As a core product of Everest Medicines, etrasimod has been approved in Singapore, Macao SAR, and Hong Kong SAR, and its NDA has been accepted in South Korea. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R). As Everest’s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Copyright 2025 ACN Newswire via SeaPRwire.com.

OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively

Results Highlights:- Revenue reached US$83.6 million, a year-on-year increase of 5.9%.- Sales volume reached 919,000 units, of which 779,000 units were proprietary products, representing a year-on-year increase of 8.6%.- Profit attributable to owners of the company increased by 5.1% year-on-year to US$19.8 million.- Core operating profit amounted to US$15.1 million, an increase of 11.4% year-on-year.- The Board declared a special dividend of HK15 cents per share to mark the Group’s 25th anniversary.- The Group maintained a sound financial position with cash and bank balances of US$237.1 million as of June 30, 2025 to support potential acquisitions and the construction of new manufacturing facilities.- The Group’s high-quality products have gained widespread recognition worldwide, resulting in revenue growth of 14.0% in the APAC market, 17.0% in the EMEA market, and 20.0% in the US market.- The Group acquired a Taiwan-based distributor in the first half of the year. It also plans to establish direct sales teams in Belgium and the Netherlands in the second half of the year, further strengthening direct presence in APAC and EMEA markets.- Leveraging its global commercialization expertise and extensive distribution network, the Group established strategic partnerships with medical device peers, thereby diversifying its product portfolio and generating additional revenue through cross-selling opportunities.HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2025 (the “Period”), reporting growth in both revenue and net profit despite an uncertain macroeconomic landscape.The Group recorded revenue of US$83.6 million, up 5.9% over the previous year, driven by strong year-on-year growth in the US market, as well as continued contributions from emerging markets in APAC and EMEA. Core operating profit, being profit attributable to the owners of the Company excluding share-based compensation, net tax credit from deferred tax asset in relation to tax losses, and finance income/costs, amounted to US$15.1 million, up by 11.4% year-on-year. Profit attributable to the owners of the Company increased by 5.1% year-on-year to US$19.8 million. Basic earnings per share was US2.40 cents (first half of 2024: US2.28 cents).As of June 30, 2025, the Group maintained a strong financial position with cash and bank balances amounting to US$237.1 million. In light of the Group’s solid financial position and in celebration of the its 25th anniversary, the Board has resolved to declare a special dividend of HK15 cents per ordinary share, demonstrating the Group’s commitment to creating value for its Shareholders. Together with the final dividend of HK10 cents per share for the year ended December 31, 2024 paid on June 16, 2025, Shareholders will receive a total dividend of HK25 cents in 2025.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Over the past 25 years, we have continuously invested in innovation and global commercial capabilities, establishing OrbusNeich’s reputation and enabling us to navigate different economic cycles. Despite macroeconomic and geopolitical challenges in the first half of 2025, our global deployment proved resilient. Growth in the US market reflected strong demand for our high-quality products, while our extensive sales network successfully captured growth opportunities in the APAC and EMEA regions. We will continue to sharpen our competitive edge by enhancing brand value through our direct sales market presence, excellent sales support, commitment to innovation, and comprehensive PCI and PTA product portfolio, while advancing safer, more effective solutions for physicians and patients and delivering long-term returns to shareholders.”Global Sales Network and Partnerships Boost Revenue GrowthOrbusNeich has built a sales network spanning over 70 countries and regions, including direct teams in 13 locations and a global distributor network, which proven integral to capturing local opportunities and demand worldwide. APAC revenue rose by 14.0% year-on-year to US$27.3 million during the Period, fueled by growth in Indonesia and increasing adoption of Scoreflex TRIO in Singapore and Malaysia. EMEA revenue grew 17.0% to US$22.4 million, driven by strong proprietary balloon product sales in key direct markets (Germany, France, Spain) and distributor markets (the UK, Slovakia, Czech Republic). Despite tariff disruptions, US revenue increased by 20.0% to US$8.0 million, boosted by a notable surge in sales volume of standard and scoring coronary balloons and peripheral balloons, including the high-priced Scoreflex NC balloon. Revenue from the Japan and PRC markets was US$16.1 million and US$9.7 million, respectively.Leveraging its widely-recognized global commercialization expertise, the Group partnered with peers pursuing international expansion to enrich its product portfolio and drive additional revenue streams. Building on the successful collaboration with SonoScape Medical Corp. involving the distribution of intravascular ultrasound (“IVUS”) products in Hong Kong and Macau last year, the Group has entered into a sole and exclusive distribution agreement with this partner to distribute its IVUS products in Singapore and Malaysia. The collaboration now covers four additional direct European markets (France, Germany, Spain, Switzerland) and six other distributor markets across Europe.Performance-Led Innovation Fuels Market Distinction and Portfolio DiversityAs of June 30, 2025, OrbusNeich had obtained more than 250 granted patents and published patent applications in key jurisdictions worldwide, as well as over 55 approved products.During the Period, the Group made progress in terms of product registrations and clinical trials, including:- Sapphire 3’s US trial progressing smoothly, with patient enrollment set to finish in Q4 2025 to support FDA submission for the CTO indication, distinguishing it from other conventional semi-compliant balloons on the market;- Obtained CE Marks for JADE PLUS and Teleport Glide, PMDA approvals for Teleport Glide and Scoreflex QUAD, FDA approvals for the COREPASS Modular Microcatheter, and NMPA approval for the guiding catheter;- Submitted registration applications for Scoreflex TRIO, Sapphire ULTRA, Sapphire NC ULTRA, Sapphire NC 24, JADE PLUS, Teleport XT and Teleport Glide to the NMPA, and applications for the Vascuaid Aspiration Catheter and GCE Large Lumen to the PMDA.Regarding the Group’s robust product pipeline, the Sapphire PTX paclitaxel drug-coated balloon, in the coronary space, is set to begin clinical trials in Japan near the end of 2025. In the peripheral space, the JADE Score balloon is expected to be submitted for PMDA approval in 2026.The joint venture OrbusNeich P&F also made significant progress in the clinical trials of TricValve in the PRC, with the number of participating sites increased to accelerate patient enrollment. In addition, it has been actively promoting TricValve’s entry into hospitals in the Greater Bay Area (“GBA”) through the Hong Kong & Macau Registered Drugs and Medical Devices Access to GBA Program. The first commercial implantation of TricValve in the Mainland of China was completed in July 2025, marking the achievement of an important milestone.Multi-Region Production Bases Mitigate Evolving Geopolitical RisksAs of June 30, 2025, OrbusNeich’s aggregate annual production capacity was approximately 2.1 million balloons and stents, with production facilities in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany. Since acquiring eucatech AG in late 2023, the Group has allocated resources to restore its production capabilities, gradually ramping up output during the Period to supply products for both sales and clinical registries.The Group completed the main structure construction of its largest R&D and production facility in Hangzhou, the PRC, in August 2025, with renovation work expected to begin in the second half of the year. The facility is scheduled to commence operations in 2027, adding an annual production capacity of 2.4 million units.Mr. Chien concluded, “We remain optimistic about the second half of 2025 due to strong momentum in emerging markets, successful proprietary product launches, and strategic partnerships. APAC and EMEA will remain our key growth drivers, with plans to transition selected markets from distributor to direct sales models to enhance revenue and market presence. In Europe, we will establish direct sales teams in Belgium and the Netherlands to expand our footprint. The Japanese market will see renewed momentum through new product launches, while in the PRC market, we will capitalize on policy support to expand product coverage and accelerate commercialization. US shipments are expected to speed up amid easing tariff disputes. Backed by OrbusNeich’s diversified portfolio, strong financial position, and economies of scale, we are well positioned to build a resilient, competitive business that delivers sustainable value to stakeholders.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements

RAS AL KHAIMAH CITY, UAE, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Ras Al Khaimah International Corporate Centre (RAK ICC) has announced significant amendments to its Foundations Regulations 2019, which took effect on 31 July 2025. The changes represent one of the most substantial updates to the regime since its introduction, reinforcing the UAE's position as a competitive jurisdiction for wealth structuring and long-term asset protection.RAK ICC Foundations are widely recognized for their flexibility, confidentiality, and legal robustness, making them a preferred choice for high-net-worth individuals, entrepreneurs, and family offices, both within the UAE and internationally. These structures are commonly used for succession planning, family governance, and consolidating diverse assets under a single legal entity.The 2025 amendments introduce stronger legal safeguards and improved governance measures which include:Firewall Provisions - Stronger protection from foreign judgments conflicting with RAK ICC Regulations.Three-Year Statute of Limitations - Limits challenges to establishment or asset transfers to three years.Cause of Action Provisions - Creditor fraud claims are limited to the specific asset involved and only if rendering the founder insolvent.Duress and Officer Protections - Nullifies actions taken under foreign legal coercion, preserving internal governance autonomy of a foundation.Strengthened Arbitration Framework - Disputes can be resolved privately with court-level powers.Private Trustee Foundation Provisions - Clarifies asset segregation and fiduciary integrity for property held in trust by a foundation.Assets held within RAK ICC Foundation will now benefit from enhanced firewall provisions, ensuring that foreign judgments conflicting with UAE law cannot be enforced against them. A new three-year limitation period has been established for challenging the formation of a foundation or the transfer of assets into it, providing greater certainty for founders and beneficiaries. The reforms also tighten creditor protection rules by requiring proof of insolvency in fraudulent transfer claims, with liability capped at the value of the disputed asset to prevent overreach into unrelated holdings.In addition, the updated regulations address governance integrity and operational resilience. Officers of a foundation who receive foreign orders inconsistent with RAK ICC law are obligated to disregard them, thereby safeguarding the autonomy of the foundation's decision-making. The framework now explicitly confirms that assets held in trust by a foundation are legally distinct and separate from foundation property, ensuring clear asset segregation. Dispute resolution has also been strengthened, with arbitration provisions expanded to grant tribunals court-like powers, enabling disputes to be resolved efficiently, confidentially, and in line with international best practices.These changes are part of RAK ICC's broader strategy to maintain a forward-looking legal and regulatory environment that meets global standards while catering to the specific needs of its client base. They reflect the jurisdiction's commitment to supporting sophisticated wealth planning strategies that balance control, privacy, and long-term security.By enhancing its Foundations regime, RAK ICC is cementing its position in the UAE as a trusted partner for those seeking secure, adaptable, and internationally compliant solutions for wealth preservation and intergenerational planning.About RAK ICCRas Al Khaimah International Corporate Centre (RAK ICC) is a corporate registry based in Ras Al Khaimah, United Arab Emirates. The organisation provides international business companies and foundations, typically used for private and business structuring, asset consolidation, and succession planning. To date, RAK ICC has incorporated thousands of international companies and supports multi-billion dirhams in structured assets. It serves high-net-worth individuals, entrepreneurs, and businesses seeking flexible and secure solutions for long-term business and wealth management.For media enquiries, contact us at:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/SOURCE: RAK ICC Copyright 2025 ACN Newswire via SeaPRwire.com.

MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - MMG Limited (“MMG”, stock code: 1208) has today announced its Interim Results with a net profit after tax of US$566.3 million. This represents more than a 600 per cent increase compared to a net profit after tax of US$79.5 million in the first half of 2024.The strong profit growth was primarily driven by increased copper production across all three copper mines, higher market prices for copper, gold, silver and zinc, as well as reduced unit costs at Las Bambas driven by higher copper production.“Over the first half of the year, our business delivered an outstanding operational and financial performance,” said Ivo Zhao, MMG’s CEO. “This result reflects the strength of our portfolio, the capability of our people, and the disciplined execution of our strategy.”Importantly, MMG’s safety performance improved with a total recordable injury frequency (TRIF) of 1.81 per million hours worked in the first half of 2025, an improvement compared to the full-year 2024 TRIF of 2.06. The significant events with energy exchange frequency (SEEEF) for the first half of 2025 remained consistent with the 2024 figure at 0.78 per million hours worked.Operationally, MMG achieved impressive copper sales and significantly improved production across all three of its copper assets, including a strong performance from Las Bambas and the ramp-up at Khoemacau and Kinsevere. Its Australian operations also maintained solid zinc production, despite navigating challenges including weather impacts, equipment reliability and lower grades due to mining sequence.Highlights include:Record first-half results for both EBITDA and EBIT, with EBITDA at US$1,539.9 million, representing a 98 per cent increase compared to the first half of 2024, and EBIT totalling US$1,058.8 million, an increase of 240 per cent over the same period.Net profit after tax was US$566.3 million, including a profit of US$340.0 million attributable to equity holders of the company.A 130 per cent increase in net cash flow from operations, totalling US$1,185.0 million, compared to the first half of 2024. This performance was mainly driven by increased copper sales and higher commodity prices.Balance sheet improvements, with record lows - since the acquisition of Las Bambas - in both net debt and gearing ratio. The Company’s net debt declined by US$903.3 million since the end of 2024, attributed to robust operational cash flow and the early repayment of US$500 million in Khoemacau Joint Venture Group borrowings. Gearing reduced from 41 per cent to 33 per cent over the first half of 2025.Record high total payable copper sales since 2018, reaching 237,651 tonnes in the first half of 2025.Las Bambas produced 210,637 tonnes of copper in copper concentrate in the first half of 2025, marking a 67 per cent increase compared to the same period in 2024. EBITDA reached a record high of US$1,310.5 million, representing a 122 per cent increase compared to the first half of 2024.“MMG’s balance sheet is in great shape – its strongest in 10 years - with debt reduction driven by higher profits and cash generation,” continued Mr Zhao. “Our ambition to become a top 10 global copper producer is within reach and we are well-positioned to achieve this through operational excellence, disciplined capital allocation, and a continued commitment to responsible mining.”Guidance for the year remains unchanged with total production aiming for a high end of 522,000 tonnes of copper and 240,000 tonnes of zinc. Las Bambas is expected to produce up to 400,000 tonnes of copper this year, assuming stable operating conditions and limited external disruptions. MMG is focussed on delivering its cost targets, with Las Bambas and Rosebery favourably adjusting their C1 cost range to reflect improved by-product credits and strong market conditions.The company is working to complete the recent Nickel Brazil acquisition and is confident in the long-term portfolio and growth contribution. MMG remains committed to supporting community development, strong local economies and employment and supplying the critical minerals the world needs for a sustainable future.Read the 2025 Interim Results announcement, watch a short CEO message and download company photos.About MMG Founded in 2009, MMG’s vision is to create a leading international mining company for a low carbon future. The company is headquartered in Melbourne, Australia and Beijing, China and listed on the Hong Kong Stock Exchange (HKEX1208). MMG’s portfolio supports copper, zinc and cobalt production, with soon to be nickel – products that are critical to achieving global decarbonisation and electrification targets. With operations in Australia, Botswana, the Democratic Republic of Congo and Latin America. More info here.  Copyright 2025 ACN Newswire via SeaPRwire.com.